Treatment-Resistant Depression Pipeline: 25+ Companies Advancing the Future of Treatment

Leading pharmaceutical companies are driving innovation in the Treatment-Resistant Depression pipeline, shaping the future of treatment and unlocking new growth opportunities.

DelveInsight's 'Treatment-Resistant Depression Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Treatment-Resistant Depression therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Treatment-Resistant Depression pipeline domain.

For Treatment-Resistant Depression emerging drugs, the Treatment-Resistant Depression pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Treatment-Resistant Depression Pipeline Report
• DelveInsight's Treatment-Resistant Depression Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline drugs for Treatment-Resistant Depression treatment.
• The leading Treatment-Resistant Depression companies include Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, Supernus Pharmaceuticals, Beckley Psytech, and others are evaluating their lead assets to improve the Treatment-Resistant Depression treatment landscape.
• Key Treatment-Resistant Depression pipeline therapies in various stages of development include NV5138, MIJ821, REL-1017, BPL-003, COMP360, AXS-05, FALKIERI, and others.
• In January 2025, the FDA approved Johnson & Johnson's Spravato (esketamine) as the first and only standalone monotherapy for treatment-resistant depression (TRD).
• On November 13, 2024, atai Life Sciences provided an update on its pipeline during Q3 2024. Notably, the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug (IND) application for VLS-01, atai's buccal film formulation of DMT. The company plans to initiate a Phase 2 study of VLS-01 for treatment-resistant depression by year-end. Additionally, atai remains on track to launch a Phase 2 study of EMP-01 (oral R-MDMA) for social anxiety disorder by the end of 2024.
• On October 9, 2024, Denovo Biopharma LLC announced that the FDA had granted Fast Track designation for DB104 (liafensine), a drug being developed for treatment-resistant depression (TRD). This designation may expedite the review process for DB104, a drug intended for patients who have failed to respond to standard antidepressant treatments, addressing a major unmet need in mental health.

Request a sample and discover the recent breakthroughs happening in the Treatment-Resistant Depression pipeline landscape @ https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Treatment-Resistant Depression Overview
Treatment-Resistant Depression (DED) is a chronic condition that results from dysfunction of the tear film and can be debilitating. It is a complex, multifactorial condition characterized by inflammation of the ocular surface and lacrimal glands, along with reduced tear quality and/or quantity. According to the National Eye Institute, dry eye is defined as "a multifactorial disease of the tears and ocular surface that causes discomfort, visual disturbance, and tear film instability, potentially damaging the ocular surface. It is associated with increased tear film osmolarity and inflammation of the ocular surface."

DED is generally classified into two categories: aqueous deficient and evaporative. However, these categories are not mutually exclusive, and many patients experience a combination of both. Aqueous tear deficiency occurs when tear production is insufficient, often caused by conditions like Sjogren Syndrome, lacrimal gland diseases, gland obstructions, or systemic medications (such as decongestants and antihistamines). Evaporative dry eye occurs when there is excessive tear evaporation due to a deficiency in the lipid portion of the tear film. In this case, tear production is normal, but the quality of the tears leads to excessive evaporation, typically caused by meibomian gland dysfunction.

Treatment for Treatment-Resistant Depression follows a stepwise approach, varying based on severity. Initial treatments focus on educating patients about the condition, modifying environmental factors (e.g., reducing airflow, screen time, and using humidifiers), identifying and eliminating triggers, using topical lubricants, practicing lid hygiene (e.g., warm compresses and lid scrubs), and incorporating oral essential fatty acids.

For more advanced cases, treatments may include preservative-free lubricants, punctal occlusion (punctal plugs), night-time ointments or moisture goggles, meibomian gland heating/expression devices, intense pulsed light therapy, topical anti-inflammatory drugs (like corticosteroids, cyclosporine, or lifitegrast), and oral antibiotics (e.g., macrolides or tetracyclines).

Find out more about Treatment-Resistant Depression medication @ https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Treatment-Resistant Depression Treatment Analysis: Drug Profile
Psilocybin Therapy - COMPASS Pathways
Psilocybin therapy is an emerging approach under investigation for treating mental health disorders. This therapy integrates the pharmacological effects of psilocybin, a psychoactive compound found in certain mushroom species (commonly known as 'magic mushrooms'), with psychological support. COMPASS Pathways has developed a synthetic formulation of psilocybin, COMP 360, and is currently evaluating its effectiveness, particularly for treatment-resistant depression.

AXS-05 - Axsome Therapeutics
AXS-05 is an innovative, oral investigational therapy designed for central nervous system (CNS) disorders. It acts as an NMDA receptor antagonist with multimodal activity. The drug consists of a proprietary combination of dextromethorphan (DM) and bupropion. Dextromethorphan functions as an NMDA receptor antagonist and sigma-1 receptor agonist, influencing glutamatergic neurotransmission. Bupropion primarily enhances the bioavailability of dextromethorphan while also serving as a norepinephrine and dopamine reuptake inhibitor.

Key Treatment-Resistant Depression Therapies and Companies
• Psilocybin: COMPASS Pathways
• NV5138: Navitor Pharmaceuticals/Supernus Pharmaceuticals
• MIJ821: Novartis
• REL-1017: Relmada Therapeutics
• BPL-003: Beckley Psytech
• COMP360 (Psilocybin): COMPASS Pathways
• AXS-05: Axsome Therapeutics
• FALKIERI (esketamine DPI): Celon Pharma

Learn more about the novel and emerging Treatment-Resistant Depression pipeline therapies @ https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Treatment-Resistant Depression Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Treatment-Resistant Depression Pipeline Report
• Coverage: Global
• Key Treatment-Resistant Depression Companies: Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, Supernus Pharmaceuticals, Beckley Psytech, and others.
• Key Treatment-Resistant Depression Pipeline Therapies: NV5138, MIJ821, REL-1017, BPL-003, COMP360, AXS-05, FALKIERI, and others.

Dive deep into rich insights for drugs used for Treatment-Resistant Depression treatment; visit @ https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Treatment-Resistant Depression Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Treatment-Resistant Depression Pipeline Therapeutics
6. Treatment-Resistant Depression Pipeline: Late-Stage Products (Phase III)
7. Treatment-Resistant Depression Pipeline: Late-Stage Products (Phase III)
8. Treatment-Resistant Depression Pipeline: Mid-Stage Products (Phase II)
9. Treatment-Resistant Depression Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.